HF
ZNTL icon

HRT Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

HRT Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,185
Closed -$122K – 5529
2026
Q1 		$122K Buy
+52,185
New +$135K ﹤0.01% 3312
2025
Q4 		– Sell
-30,424
Closed -$45K – 4190
2025
Q3 		$45K Sell
30,424
-83,439
-73% -$125K ﹤0.01% 2617
2025
Q2 		$132K Buy
+113,863
New +$150K ﹤0.01% 2157
2025
Q1 		– Sell
-140,394
Closed -$425K – 3526
2024
Q4 		$425K Buy
140,394
+61,467
+78% +$201K ﹤0.01% 1539
2024
Q3 		$290K Buy
+78,927
New +$287K ﹤0.01% 1819
2024
Q2 		– Sell
-113,750
Closed -$1.79M – 3249
2024
Q1 		$1.79M Buy
+113,750
New +$1.56M 0.01% 620

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

HRT Financial's ZNTL Position: Q2 2026 in Review

HRT Financial sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 52,185 shares — an estimated $122K sold.

HRT Financial first reported a position in ZNTL in Q1 2024 and held it in 6 quarters. The position peaked at $1.79M in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • HRT Financial reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 52,185 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $122K.
  • HRT Financial first reported a position in Zentalis Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • HRT Financial's Zentalis Pharmaceuticals position peaked at $1.79M in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.